Spots Global Cancer Trial Database for biphenotypic acute leukemia

Every month we try and update this database with for biphenotypic acute leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)	NCT04942730	Leukemia, Acute... Myeloid Leukemi... Biphenotypic Ac... Lymphoblastic L... Myelodysplastic... Myeloproliferat...	Fludarabine Bendamustine Hy... Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus 5Mg ...	18 Years - 75 Years	St. Petersburg State Pavlov Medical University
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis	NCT05515029	Acute Lymphobla... Myeloblastic Le... Biphenotypic Ac... Malignant Lymph... Myelodysplastic... Juvenile Myelom...	GVHD prevention...	1 Day - 21 Years	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis	NCT05515029	Acute Lymphobla... Myeloblastic Le... Biphenotypic Ac... Malignant Lymph... Myelodysplastic... Juvenile Myelom...	GVHD prevention...	1 Day - 21 Years	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Allo HSCT Using RIC and PTCy for Hematological Diseases	NCT05805605	Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis	Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M...	- 75 Years	Masonic Cancer Center, University of Minnesota

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: